Opko Health Inc. (NYSE: OPK) shares are trading higher by $0.44 (5 percent) at $9.63 in Tuesday's session. The catalyst for the rally is the confirmation that the FDA has approved NDA for Rayaldee to treat certain symptoms of chronic kidney...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Opko Health Inc (OPK):